Angiopoietin-like protein 3 (ANGPTL3) has emerged as important regulators of lipid metabolism. Current innovative therapeutic options using monoclonal antibodies, antisense oligonucleotide (ASO) or vaccine approaches to block this protein may minimize the risk of atherosclerosis in dyslipidemic individuals. The purpose of this review is to discuss the effectiveness of these new ANGPTL3 inhibitors.
No takes yet. Share an insight, caveat, or question.
wanee plengpanich (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: